Bulk Manufacturer of Controlled Substances Application: Siemens Healthcare Diagnostics Inc., 13744-13745 [2024-03712]
Download as PDF
<![CDATA[
13744
Federal Register / Vol. 89, No. 37 / Friday, February 23, 2024 / Notices
A. National Historic Landmarks (NHL)
Program
Proposed Withdrawal of Existing
Designations
NHL Program matters will be
considered, during which the Board
may consider the following:
North Carolina
• JOSEPHUS DANIELS HOUSE
(WAKESTONE), Raleigh, NC.
Nominations for NHL Designation
South Carolina
• USS CLAMAGORE (former), Mount
Pleasant, SC.
Commonwealth of the Northern
Mariana Islands.
• LATTE QUARRY AT AS NIEVES,
Rota, CNMI.
• THE FURIES COLLECTIVE,
Washington, DC.
B. National Natural Landmarks (NNL)
Program
NNL Program matters will be
considered, during which the Board
may consider the following:
Kentucky
Nomination for NNL Designation
District of Columbia
• BIG BONE LICK SITE, Union, KY.
Nebraska
• KREGEL WINDMILL COMPANY
FACTORY, Nebraska City, NE.
South Carolina
• CHARLESTON CIGAR FACTORY,
Charleston, SC.
Proposed Amendments to Existing NHL
Designations
Alaska
• SITKA NAVAL OPERATING BASE
AND U.S. ARMY COASTAL DEFENSES
(updated documentation), Sitka, AK.
• LADD FIELD (updated
documentation), Fairbanks, AK.
Hawai1i
¯ HEIAU (updated
• PU1UKOHOLA
documentation, boundary change),
Kawaihae, HI.
Michigan
• QUINCY MINING COMPANY
HISTORIC DISTRICT (updated
documentation, boundary change),
Houghton County, MI.
• CALUMET HISTORIC DISTRICT
(updated documentation, boundary
change), Calumet, MI.
Missouri
• WATKINS MILL (updated
documentation), Lawson, MO.
Texas
• FORT BROWN (updated
documentation, boundary change),
Brownsville, TX.
ddrumheller on DSK120RN23PROD with NOTICES1
Virginia
• CEDAR CREEK BATTLEFIELD
AND BELLE GROVE (updated
documentation, boundary change),
Middletown, VA.
Wyoming
• WYOMING STATE CAPITOL
BUILDING AND GROUNDS (updated
documentation), Cheyenne, WY.
VerDate Sep<11>2014
17:19 Feb 22, 2024
Jkt 262001
Texas
• INDEPENDENCE CREEK
PRESERVE, Terrell County, TX.
Interested persons may choose to
make oral comments at the meeting
during the designated time for this
purpose. Depending on the number of
people wishing to comment and the
time available, the amount of time for
oral comments may be limited.
Interested parties should contact
Monique VanLandingham (see FOR
FURTHER INFORMATION CONTACT) for
advance placement on the public
speaker list for this meeting. Members of
the public may also choose to submit
written comments by emailing them to
monique_vanlandingham@
partner.nps.gov. Due to time constraints
during the meeting, the Board is not
able to read written public comments
submitted into the record. All comments
will be made part of the public record
and will be electronically distributed to
all Board members. Detailed minutes of
the meeting will be available for public
inspection within 90 days of the
meeting.
Meeting Accessibility/Special
Accommodations: Please make requests
in advance for sign language interpreter
services, assistive listening devices, or
other reasonable accommodations. We
ask that you contact the person listed in
the FOR FURTHER INFORMATION CONTACT
section of this notice at least seven (7)
business days prior to the meeting to
give the Department of the Interior
sufficient time to process your request.
All reasonable accommodation requests
are managed on a case-by-case basis.
Public Disclosure of Comments:
Before including your address, phone
number, email address, or other
personal identifying information in your
comment, you should be aware that
your entire comment—including your
personal identifying information—may
be made publicly available at any time.
While you can ask us in your comment
to withhold your personal identifying
PO 00000
Frm 00066
Fmt 4703
Sfmt 4703
information from public review, we
cannot guarantee that we will be able to
do so.
Authority: 5 U.S.C. Ch. 10.
Alma Ripps,
Chief, Office of Policy.
[FR Doc. 2024–03755 Filed 2–22–24; 8:45 am]
BILLING CODE 4312–52–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–1322]
Bulk Manufacturer of Controlled
Substances Application: Siemens
Healthcare Diagnostics Inc.
Drug Enforcement
Administration, Justice.
ACTION: Notice of application.
AGENCY:
Siemens Healthcare
Diagnostics Inc. has applied to be
registered as a bulk manufacturer of
basic class(es) of controlled
substance(s). Refer to SUPPLEMENTARY
INFORMATION listed below for further
drug information.
DATES: Registered bulk manufacturers of
the affected basic class(es), and
applicants therefore, may submit
electronic comments on or objections to
the issuance of the proposed registration
on or before April 23, 2024. Such
persons may also file a written request
for a hearing on the application on or
before April 23, 2024.
ADDRESSES: The Drug Enforcement
Administration (DEA) requires that all
comments be submitted electronically
through the Federal eRulemaking Portal,
which provides the ability to type short
comments directly into the comment
field on the web page or attach a file for
lengthier comments. Please go to
https://www.regulations.gov and follow
the online instructions at that site for
submitting comments. Upon submission
of your comment, you will receive a
Comment Tracking Number. Please be
aware that submitted comments are not
instantaneously available for public
view on https://www.regulations.gov. If
you have received a Comment Tracking
Number, your comment has been
successfully submitted and there is no
need to resubmit the same comment.
SUPPLEMENTARY INFORMATION: In
accordance with 21 CFR 1301.33(a), this
is notice that on January 10, 2024,
Siemens Healthcare Diagnostics Inc.,
100 GBC Drive, Mailstop 108, Newark,
Delaware 19702–2461 applied to be
registered as a bulk manufacturer of the
following basic class(es) of controlled
substance(s):
SUMMARY:
E:\FR\FM\23FEN1.SGM
23FEN1
13745
Federal Register / Vol. 89, No. 37 / Friday, February 23, 2024 / Notices
Controlled substance
Ecgonine ..........................
Drug
code
Schedule
I 9180 III
The company plans to produce the
listed controlled substance in bulk to be
used in the manufacture of the DEA
exempt products. No other activities for
this drug code is authorized for this
registration.
Marsha Ikner,
Acting Deputy Assistant Administrator.
[FR Doc. 2024–03712 Filed 2–22–24; 8:45 am]
BILLING CODE P
DEPARTMENT OF JUSTICE
Attn: Hearing Clerk/OALJ, 8701
Morrissette Drive, Springfield, Virginia
22152; and (2) Drug Enforcement
Administration, Attn: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152. All requests for a hearing should
also be sent to: Drug Enforcement
Administration, Attn: Administrator,
8701 Morrissette Drive, Springfield,
Virginia 22152.
SUPPLEMENTARY INFORMATION: In
accordance with 21 CFR 1301.34(a), this
is notice that on January 17, 2024,
Meridian Medical Technologies, LLC,
2555 Hermelin Drive, Saint Louis,
Missouri 63144, applied to be registered
as an importer of the following basic
class(es) of controlled substance(s):
Drug Enforcement Administration
Importer of Controlled Substances
Application: Meridian Medical
Technologies, LLC
Morphine ..........................
Drug Enforcement
Administration, Justice.
ACTION: Notice of application.
AGENCY:
Meridian Medical
Technologies, LLC has applied to be
registered as an importer of basic
class(es) of controlled substance(s).
Refer to SUPPLEMENTARY INFORMATION
listed below for further drug
information.
SUMMARY:
Registered bulk manufacturers of
the affected basic class(es), and
applicants therefore, may submit
electronic comments on or objections to
the issuance of the proposed registration
on or before March 25, 2024. Such
persons may also file a written request
for a hearing on the application on or
before March 25, 2024.
ADDRESSES: The Drug Enforcement
Administration requires that all
comments be submitted electronically
through the Federal eRulemaking Portal,
which provides the ability to type short
comments directly into the comment
field on the web page or attach a file for
lengthier comments. Please go to
https://www.regulations.gov and follow
the online instructions at that site for
submitting comments. Upon submission
of your comment, you will receive a
Comment Tracking Number. Please be
aware that submitted comments are not
instantaneously available for public
view on https://www.regulations.gov. If
you have received a Comment Tracking
Number, your comment has been
successfully submitted and there is no
need to resubmit the same comment. All
requests for a hearing must be sent to:
(1) Drug Enforcement Administration,
ddrumheller on DSK120RN23PROD with NOTICES1
DATES:
VerDate Sep<11>2014
17:19 Feb 22, 2024
Drug
code
Controlled substance
[Docket No. DEA–1323]
Jkt 262001
I
9300
Schedule
III
The company plans to import the
listed controlled substances for
analytical purposely only. No other
activities for these drug codes are
authorized for this registration.
Approval of permit applications will
occur only when the registrant’s
business activity is consistent with what
is authorized under 21 U.S.C. 952(a)(2).
Authorization will not extend to the
import of Food and Drug
Administration-approved or nonapproved finished dosage forms for
commercial sale.
Marsha Ikner,
Acting Deputy Assistant Administrator.
[FR Doc. 2024–03714 Filed 2–22–24; 8:45 am]
BILLING CODE P
DEPARTMENT OF JUSTICE
persons may also file a written request
for a hearing on the application on or
before March 25, 2024.
The Drug Enforcement
Administration requires that all
comments be submitted electronically
through the Federal eRulemaking Portal,
which provides the ability to type short
comments directly into the comment
field on the web page or attach a file for
lengthier comments. Please go to
https://www.regulations.gov and follow
the online instructions at that site for
submitting comments. Upon submission
of your comment, you will receive a
Comment Tracking Number. Please be
aware that submitted comments are not
instantaneously available for public
view on https://www.regulations.gov. If
you have received a Comment Tracking
Number, your comment has been
successfully submitted and there is no
need to resubmit the same comment. All
requests for a hearing must be sent to:
(1) Drug Enforcement Administration,
Attn: Hearing Clerk/OALJ, 8701
Morrissette Drive, Springfield, Virginia
22152; and (2) Drug Enforcement
Administration, Attn: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152. All requests for a hearing should
also be sent to: Drug Enforcement
Administration, Attn: Administrator,
8701 Morrissette Drive, Springfield,
Virginia 22152.
ADDRESSES:
In
accordance with 21 CFR 1301.34(a), this
is notice that on January 11, 2024, Pall
Life Sciences PR, LLC, Road 194,
Kilometer 0.4, Fajardo, Puerto Rico
00738, applied to be registered as an
importer of the following basic class(es)
of controlled substance(s):
SUPPLEMENTARY INFORMATION:
Drug Enforcement Administration
Importer of Controlled Substances
Application: Pall Life Sciences PR, LLC
Drug Enforcement
Administration, Justice.
ACTION: Notice of application.
AGENCY:
Pall Life Sciences PR, LLC has
applied to be registered as an importer
of basic class(es) of controlled
substance(s). Refer to SUPPLEMENTARY
INFORMATION listed below for further
drug information.
DATES: Registered bulk manufacturers of
the affected basic class(es), and
applicants therefore, may submit
electronic comments on or objections to
the issuance of the proposed registration
on or before March 25, 2024. Such
SUMMARY:
PO 00000
Frm 00067
Fmt 4703
Drug
code
Controlled substance
[Docket No. DEA–1318]
Sfmt 4703
Morphine ..........................
I
9300
Schedule
III
The company plans to import the
listed controlled substances for research
purposes, drug testing, and analysis to
support foreign regulatory compliance
of finished dosage forms to foreign
markets. No other activities for these
drug codes are authorized for this
registration.
Approval of permit applications will
occur only when the registrant’s
business activity is consistent with what
is authorized under 21 U.S.C. 952(a)(2).
Authorization will not extend to the
import of Food and Drug
Administration-approved or non-
E:\FR\FM\23FEN1.SGM
23FEN1
]]>Agencies
[Federal Register Volume 89, Number 37 (Friday, February 23, 2024)]
[Notices]
[Pages 13744-13745]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-03712]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-1322]
Bulk Manufacturer of Controlled Substances Application: Siemens
Healthcare Diagnostics Inc.
AGENCY: Drug Enforcement Administration, Justice.
ACTION: Notice of application.
-----------------------------------------------------------------------
SUMMARY: Siemens Healthcare Diagnostics Inc. has applied to be
registered as a bulk manufacturer of basic class(es) of controlled
substance(s). Refer to Supplementary Information listed below for
further drug information.
DATES: Registered bulk manufacturers of the affected basic class(es),
and applicants therefore, may submit electronic comments on or
objections to the issuance of the proposed registration on or before
April 23, 2024. Such persons may also file a written request for a
hearing on the application on or before April 23, 2024.
ADDRESSES: The Drug Enforcement Administration (DEA) requires that all
comments be submitted electronically through the Federal eRulemaking
Portal, which provides the ability to type short comments directly into
the comment field on the web page or attach a file for lengthier
comments. Please go to https://www.regulations.gov and follow the
online instructions at that site for submitting comments. Upon
submission of your comment, you will receive a Comment Tracking Number.
Please be aware that submitted comments are not instantaneously
available for public view on https://www.regulations.gov. If you have
received a Comment Tracking Number, your comment has been successfully
submitted and there is no need to resubmit the same comment.
SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.33(a), this
is notice that on January 10, 2024, Siemens Healthcare Diagnostics
Inc., 100 GBC Drive, Mailstop 108, Newark, Delaware 19702-2461 applied
to be registered as a bulk manufacturer of the following basic
class(es) of controlled substance(s):
[[Page 13745]]
------------------------------------------------------------------------
Drug
Controlled substance code Schedule
------------------------------------------------------------------------
Ecgonine................................ 9180 II
------------------------------------------------------------------------
The company plans to produce the listed controlled substance in
bulk to be used in the manufacture of the DEA exempt products. No other
activities for this drug code is authorized for this registration.
Marsha Ikner,
Acting Deputy Assistant Administrator.
[FR Doc. 2024-03712 Filed 2-22-24; 8:45 am]
BILLING CODE P
